Helus Pharma CEO to join TD Cowen neuropsychiatry summit fireside chat
Michael Halstead will take part in a virtual fireside chat on September 23, 2026 at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit.
SEC filing
Latest
8 stories
Monday, September 21
Thursday, September 10
Cybin's Helus Pharma to join three investor conferences in New York in September 2026
CEO Michael Halstead will hold fireside chats at Cantor, H.C. Wainwright, and Morgan Stanley healthcare conferences between September 11 and 16, 2026.
SEC filing (3)
Tuesday, September 1
Cybin discloses Form D for stock option grant tied to $11.78 strike price
The filing covers options set to vest over eight quarterly installments starting August 19, 2026, with a total potential offering value of $261,987.
SEC filing
Wednesday, August 19
Cybin files two Form D notices for equity awards to executives and directors
The Toronto-based company registered separate exempt offerings covering restricted share units and performance share units, both dated August 18, 2026.
SEC filing (2)
Tuesday, August 18
Helus Pharma names Intra-Cellular veterans to leadership and advisory roles
Cybin's commercial unit Helus Pharma added a Chief People Officer and a Scientific Advisory Board member, both formerly of Intra-Cellular Therapies.
SEC filing (2)
Monday, August 10
Helus Pharma names Michael Halstead CEO ahead of HLP003 Phase 3 readout
The former Intra-Cellular Therapies president takes over as topline data from the first pivotal study of HLP003 in major depressive disorder are expected in the fourth quarter of 2026.
SEC filing (2)
Tuesday, July 21
Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003 for MDD
The trial, testing HLP003 as an adjunctive MDD treatment, finished enrollment ahead of schedule with topline data still expected in Q4 2026.
SEC filing
Wednesday, July 15
Cybin discloses two Form D filings for stock options and RSUs
Cybin Inc. registered separate exempt offerings covering employee stock options and restricted share units, both dated for first sale on July 1, 2026.
SEC filing (2)